Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
- 12 March 2001
- journal article
- Published by Wiley in Movement Disorders
- Vol. 16 (2) , 197-201
- https://doi.org/10.1002/mds.1069
Abstract
Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.Keywords
This publication has 36 references indexed in Scilit:
- Long‐duration response to levodopa influences the pharmacodynamics of short‐duration response in Parkinson's diseaseAnnals of Neurology, 1997
- NEUROBIOLOGY OF l-DOPAergic SYSTEMSProgress in Neurobiology, 1996
- The subacute levodopa test for evaluating long‐duration response in parkinson's diseaseAnnals of Neurology, 1995
- Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Dopamine agonists in Parkinson's disease: a look at apomorphineFundamental & Clinical Pharmacology, 1993
- Apomorphine test for dopaminergic responsiveness: A dose assessment studyMovement Disorders, 1993
- Intravenous boluses and continuous infusions ofL-DOPA methyl ester in fluctuating patients with Parkinson's diseaseMovement Disorders, 1992
- Levodopa‐induced diphasic dyskinesias improved by subcutaneous apomorphineMovement Disorders, 1992
- Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromesThe Lancet, 1990